Successful treatment of disseminated extragonadal germ cell cancer with intensive conventional chemotherapy after first-line high-dose chemotherapy

International Journal of Clinical Oncology
Takeshi YuasaYusaku Okada

Abstract

High-dose chemotherapy (HDCT) with peripheral blood stem cell (PBSC) support has been investigated as a first-line treatment in patients with poor risk germ cell cancer. However, effective management of patients with residual cancer after HDCT has not been well addressed, and the outcome in such patients is poor. Here, we report a case of disseminated germ cell cancer successfully treated with intensive conventional chemotherapy after HDCT. A 31-year-old man presented with a bulky mass at the retroperitoneum, which had invaded the lumbar and sacral vertebra, and multiple lung and liver metastases. The patient's serum beta subunit of human chorionic gonadotrophin (beta-hCG) was elevated to 2600 IU (cut-off value <0.1 IU). At the time of diagnosis of poor risk germ cell cancer of extragonadal origin, he underwent two cycles of BEP (bleomycin, etoposide, and cisplatin) chemotherapy and PBSC harvest followed by three cycles of HDCT with PBSC transplantation. The liver metastases disappeared. The retroperitoneal bulky mass and multiple lung metastases shrank but were still present, and the serum beta-hCG level was not completely normalized. An additional three courses of BEP and five courses of VIP (cisplatin, ifosfamide, etoposide)...Continue Reading

References

Jul 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R J MotzerV Vlamis
Nov 5, 1997·Journal of the National Cancer Institute·L B TravisJ D Boice
Apr 29, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R T ZonL H Einhorn
Mar 18, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C BokemeyerL Kanz
Jun 10, 2000·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M P DecatrisM Dougall
Dec 19, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J M O'SullivanA Horwich
Feb 25, 2003·Cancer Control : Journal of the Moffitt Cancer Center·Ugo De GiorgiGiovanni Rosti
Mar 26, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C KollmannsbergerC Bokemeyer
Sep 25, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A BerrutiL Dogliotti

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.